Oral Idarubicin
Micaela M. Buckley,Harriet M. Lamb
DOI: https://doi.org/10.2165/00002512-199711010-00006
1997-07-01
Abstract:SynopsisIdarubicin is an anthracycline agent available as both oral and intravenous formulations. The oral formulation has demonstrated efficacy in the treatment of advanced breast cancer, low-grade non-Hodgkin’s lymphoma, myelodysplastic syndromes and as first-line induction therapy of acute myelogenous leukaemia where intravenous anthracycline treatment is precluded. It also has potential in ameliorating blast crisis of chronic myelogenous leukaemia and in multiple myeloma.The most frequent adverse effects associated with oral idarubicin are those commonly found with anthracyclines, namely myelosuppression, nausea and vomiting, diarrhoea and mucositis. There appears to be minimal significant cardiotoxicity with oral idarubicin.In summary, available data concerning oral idarubicin in haematological malignancies and advanced breast cancer are sufficiently encouraging to warrant further research. To maximise the use of oral idarubicin, future studies should define the optimal dose for elderly patients, its comparative efficacy with other available regimens and address quality-of-life and pharmacoeconomic issues associated with the substitution of oral for intravenous chemotherapy.Pharmacodynamic PropertiesIdarubicin is an analogue of daunorubicin, with greater lipophilicity and consequent improved absorption across the gastrointestinal mucosa and enhanced uptake into tumour cells. The major metabolite of idarubicin, idarubicinol, is pharmacologically active, with similar activity in vitro and in vivo to the parent compound. In murine experimental tumour systems, oral idarubicin produced equivalent activity to the intravenous formulation at an approximately 4-fold higher dose. In vivo cytotoxic activity was 4 to 8 times greater than that of either daunorubicin or doxorubicin in models of leukaemias and lymphomas.The putative mechanism of cytotoxic activity of idarubicin is through interference with DNA synthesis, by means of intercalation between the DNA bases and inhibition of DNA topoisomerase II.Animal studies indicate that intravenous idarubicin has less cardiotoxic potential than other anthracyclines, with oral administration further reducing cardiotoxicity.The in vitro activity of idarubicin and idarubicinol is less affected than that of other anthracyclines in multidrug resistant human cancer and leukaemia cell lines compared with sensitive cells.Pharmacokinetic PropertiesIdarubicin is rapidly absorbed after oral administration, with drug concentrations detectable in plasma within 30 minutes. Peak plasma concentrations are observed after between 1 and 9 hours. The proportion of metabolite present in plasma relative to the parent drug is markedly greater after oral than after intravenous administration, reflecting first-pass hepatic metabolism.Idarubicin and its metabolite are both extensively plasma protein bound, and the drug also undergoes extensive tissue uptake, reflected in a large apparent volume of distribution (1214 to 1889 L/m2).The principal metabolite, idarubicinol, is formed by reduction of the ketone on carbon 13 in a reaction common to anthracyclines. Rapid transformation to idarubicinol probably accounts for the high total plasma clearance of idarubicin. The plasma elimination half-life (t½) of idarubicin after oral administration is 5 to 24 hours, and that for idarubicinol is between 13 and 60 hours.Biliary excretion is the primary route of elimination of idarubicin, as for other anthracyclines, but the relative contribution of this route to idarubicin excretion remains to be determined. Urinary excretion is only a minor route of idarubicin, in common with other anthracyclines.The bioavailability of idarubicin is independent of age, and it is unlikely that the pharmacokinetics of idarubicin are altered in elderly patients. Total plasma clearance is significantly reduced in patients with impaired renal function (creatinine clearance <60 ml/min); in addition, the terminal phase t½ of idarubicinol was prolonged.Clinical EfficacyHaematological Malignancies: Oral idarubicin has shown particular efficacy in some haematological malignancies. In noncomparative studies of oral idarubicin as induction monotherapy of acute myelogenous leukaemia (AML) in elderly patients, rates of complete response were between 5 and 40%, with overall or objective (complete plus partial response) responses observed in 10 to 80% of patients. When oral idarubicin was administered as induction therapy in combination with subcutaneous cytarabine, complete response rates were between 41 and 54%, with overall response rates of 47 to 62%. An attenuated- or low-dose oral regimen of idarubicin, etoposide and thioguanine also compared favourably with an oral/intravenous regimen of cytarabine, daunorubicin and thioguanine in terms of both response rates and survival.The use of oral idarubicin monotherapy in the treatment of myelodysplastic syndromes in elderly patients appears warranted, although further investigation to determine optimal dosage regimens may be necessary. Oral idarubicin was also effective in a small trial of palliative therapy in patients with chronic myelogenous leukaemia in blast crisis, in whom quality of life is an important treatment outcome.Although treatment-related adverse effects have at times led to somewhat equivocal results with oral idarubicin in patients with multiple myeloma, substantial overall response rates (58 to 66%) observed with oral combination therapy incorporating idarubicin merit further research.Significant activity of oral idarubicin is apparent from trials in non-Hodgkin’s lymphoma, particularly in patients without prior therapy and with favourable (low-grade) histology. Overall responses to monotherapy ranged from 26 to 65%, with a median response duration of about 6 months. Combination regimens have also proved effective, but their risk-benefit profile in elderly patients remains to be fully established.Advanced Breast Cancer: In early noncomparative trials, oral idarubicin monotherapy produced overall objective response rates ranging between 13 and 36% in patients with advanced breast cancer. The highest rate of complete response achieved was 11 % in a trial in chemotherapy-naive patients aged between 70 and 84 years. Most patients received intermittent regimens.In trials comparing oral idarubicin 45 mg/m2/day with intravenous doxorubicin 75 mg/m2/day, differing results have been obtained: in one trial overall objective response rates were 30% with idarubicin and 32% with doxorubicin, with a similar duration of response and survival. However, a second study observed an overall response of 21% with idarubicin versus 46% with doxorubicin. Median response durations were similar, but median survival was 14 months with idarubicin and 20 months with doxorubicin.Oral idarubicin in combination with cyclophosphamide has produced overall response rates of between 22 and 49%. The median duration of response in these trials was about 7 months. A 3-drug regimen combining oral idarubicin with cyclophosphamide and fluorouracil has also proven effective with a response rate of 53% reported.TolerabilityIdarubicin appears to produce less cardiotoxicity than other anthracyclines, with clinically significant alterations in cardiac function observed infrequently.Most patients treated with idarubicin experience myelosuppression, the severity of which is dose dependent. A review of 1399 patients treated with oral idarubicin for solid tumours evinced an incidence of deaths attributable to drug-related toxicity of 1%, although haemopoietic growth factors were not used in any patient. Haematological parameters appear to normalise in most patients after 3 to 4 week’ therapy.Gastrointestinal adverse events occur frequently and may be more pronounced after oral idarubicin than after an equivalent intravenous dose. The most common events are nausea and vomiting occurring in up to 25 to 86% of patients. Diarrhoea develops in about 10 to 38% of patients receiving oral idarubicin, with mucositis apparent in about 9%. Alopecia occurred in about 35% of patients with solid tumours receiving oral idarubicin 40 to 45 mg/m2 per cycle, but was of moderate severity.Dosage and AdministrationFor remission induction in patients with AML for whom intravenous therapy is unsuitable, oral idarubicin is effective at a dosage of 30 mg/m2 daily as mono-therapy or 15 to 30 mg/m2 daily for 3 days in combination regimens. In myelodysplastic syndromes, oral idarubicin 50 mg/m2 in 4 divided doses every 2 to 4 weeks or as a single 50mg dose every 3 to 4 weeks have been effective in elderly patients. In patients with non-Hodgkin’s lymphoma, effective doses ranged from 30 to 45 mg/m2 administered every 3 weeks.In the treatment of advanced breast cancer, oral idarubicin at a dosage of about 45 mg/m2 every 3 or 4 weeks provides effective monotherapy for patients in whom the disease is refractory to first-line non-anthracycline chemotherapy.Cardiotoxicity appears unlikely with cumulative oral doses up to 400 mg/m2. Cardiac, renal and hepatic function should be monitored during therapy, and regular peripheral blood counts taken. Dosage reduction may be necessary when bilirubin or creatinine levels are markedly increased.
pharmacology & pharmacy,geriatrics & gerontology,gerontology